OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
March 13, 2024
The company is investing more than $2 million in its analytical testing services and adding suppository manufacturing capabilities.
March 12, 2024
In an interview, Fabian Gerlinghaus of Cellares outlines a paradigm change in both hardware and software, regulatory expansions, and some positive cost outcomes for the CGT field.
The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.
The European company has seen its business increase by 47% in North America.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.
EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
FDA has published final guidance documents regarding validation and development of analytical procedures.